Abstract 309P
Background
Immunotherapy with lenvatinib plus pembrolizumab (LP) prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced endometrial cancer. However, the predictive biomarker for this therapy is still unclear. Some studies on breast and prostate cancer have suggested that expression of hormone receptors (HRs) has immune regulatory functions. Therefore, we explored whether the HRs expression could be a predictive biomarker of LP therapy.
Methods
We retrospectively reviewed clinicopathological information on patients with advanced mismatch repair proficient (pMMR) endometrial cancer who underwent LP therapy between January 2022 and March 2023 at the National Cancer Center Hospital. Expression of HRs was evaluated for estrogen receptor (ER) and progesterone receptor (PR) by immunohistochemistry. Cases were dichotomized, using 10% as a cut-off value. Expression of p53 and programmed cell death ligand-1 (PD-L1) were also confirmed. PFS and OS were compared according to the status of HRs, p53, and PD-L1 expressions by log-rank test. Multivariate analysis using Cox proportional hazard model was performed to confirm the prognosis factor.
Results
A total of 19 patients were reviewed, including four patients with carcinosarcoma. Twelve patients were ER-positive and 11 were PR-positive. Thirteen had an aberrant type of p53 expression and, 14 had PD-L1 positive (combined positive score ≥ 1). No association was found between prognosis and expression status of PR, p53, or PD-L1. However, patients with ER-positive had a significantly poorer PFS (4.3 vs. 10.0 months, hazard ratio [HR]: 3.28, p = 0.038) than those with ER-negative. Multivariate analysis confirmed that ER-positive is a statistically poor prognostic factor for PFS. Similarly, ER-positive patients tended to have a poorer OS (6.2 vs. 11.5 months, HR: 1.92, p = 0.375) than ER-negative patients. Overall response rate was 42% and 71% for ER-positive and negative patients, respectively.
Conclusions
ER expression was associated with shorter PFS of LP therapy. ER expression in tumors was a negative predictive biomarker in LP therapy for advanced endometrial cancer with pMMR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Nishikawa: Financial Interests, Personal, Invited Speaker: MSD, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract